IO Biotech Appoints Christine Richter, Ph.D., MBA, as Senior Vice President, Commercial and Program Lead
June 01 2023 - 8:30AM
IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical
company developing novel, immune-modulating cancer vaccines based
on its T-win® technology platform, announced today that biopharma
executive Christine Richter joined the company as SVP, Commercial
and Program Lead for IO102-IO103, the company’s lead cancer vaccine
candidate. Dr. Richter will report to IO Biotech’s CEO, Mai-Britt
Zocca, Ph.D., and will be a member of the company’s executive team.
“Nearing the recruitment of 225 patients in our
global Phase 3 clinical trial for IO102-IO103 in patients with
advanced metastatic melanoma, we now expect to have a clear line of
sight on both the interim analysis next year and a potential U.S.
Biologics License Application filing,” said Dr. Zocca. “While we
continue our keen focus on the execution of our clinical programs,
now is the time to elevate program management and initiate
commercial readiness activities. I am very pleased to welcome
Christine to IO Biotech. We look forward to the strategic insights
she will bring as we progress into the commercial readiness
phase.”
Dr. Richter added, “There is no better time to
be joining IO Biotech. I believe that our approach to cancer
vaccines could potentially change the treatment paradigm. I look
forward to working with this high-caliber team to realize our goal
of delivering a groundbreaking therapy to patients with cancer who
might benefit.”
Dr. Richter is an accomplished pharma/biotech
executive with a proven track record of success in management and
commercial leadership within both the U.S. and international
markets at leading companies including Amgen, Takeda Oncology, and
most recently LEO Pharma. She has spent most of her career at
Amgen, predominantly in Oncology/Hematology with additional work in
General Medicine, and Rare Diseases. Dr. Richter holds a Ph.D. in
Cancer Immunotherapy from the Ludwig-Maximilian University of
Munich, and an MBA in Health Care Management from the University of
Bayreuth.
About IO Biotech
IO Biotech is a clinical-stage biopharmaceutical
company developing novel, immune-modulating cancer vaccines based
on its T-win® vaccine platform. The T-win platform is a novel
approach to cancer vaccines designed to activate T cells to target
the most important immunosuppressive cells in the tumor
microenvironment. IO Biotech is advancing in clinical studies its
lead cancer vaccine candidate, IO102-IO103, targeting IDO and
PD-L1, and through preclinical development its other pipeline
candidates. IO Biotech is headquartered in Copenhagen, Denmark and
has US headquarters in New York, New York.
For further information, please visit
www.iobiotech.com.
Forward-Looking Statement
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Forward-looking statements, including
regarding future clinical trials and results, are based on IO
Biotech’s current assumptions and expectations of future events and
trends, which affect or may affect its business, strategy,
operations or financial performance, and actual results and other
events may differ materially from those expressed or implied in
such statements due to numerous risks and uncertainties.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified.
Because forward-looking statements are inherently subject to risks
and uncertainties, you should not rely on these forward-looking
statements as predictions of future events. These forward-looking
statements speak only as of the date hereof and should not be
unduly relied upon. Except to the extent required by law, IO
Biotech undertakes no obligation to update these statements,
whether as a result of any new information, future developments or
otherwise.
Contact:Maryann Cimino, Director of Investor
Relations IO Biotech, Inc.617-710-7305mci@iobiotech.com
IO Biotech (NASDAQ:IOBT)
Historical Stock Chart
From May 2024 to Jun 2024
IO Biotech (NASDAQ:IOBT)
Historical Stock Chart
From Jun 2023 to Jun 2024